Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EPS (Weighted Average and Diluted) (2024 - 2025)

Indivior Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 2 years, most recently at $0.79 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.79 for Q4 2025, up 393.75% from a year ago — trailing twelve months through Dec 2025 was $1.64 (up 3180.0% YoY), and the annual figure for FY2025 was $1.64, up 3180.0%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.79 at Indivior Pharmaceuticals, up from $0.33 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for INDV hit a ceiling of $0.79 in Q4 2025 and a floor of -$0.72 in Q2 2024.